The rising cases of chronic obstructive pulmonary diseases (COPDs), diabetes, cancer, and cardiovascular diseases (CVDs) have amplified the adoption of minimally invasive blood-drawing devices such as lancets. According to the World Health Organization (WHO), currently nearly 235 million people are suffering from asthma and around 3 million individuals die due to COPDs each year. The organization also states that cancer kills around 9.6 million people and heart diseases claim 17.9 million human lives each year. Medical professionals use lancets to diagnose such diseases at their early stages to reduce the mortality rate.

Access Detailed Report - Lancet Market Revenue Estimation

Additionally, the escalating adoption of such medical devices in homecare settings will fuel the lancet market at a CAGR of 9.5% during the forecast period (2020–2030). The market generated $830.3 million revenue in 2019. Lancets made for homecare settings are easier to utilize than those applied in hospitals and clinics. Owing to their easy availability and usage, the devices are gaining wide popularity among the geriatric population, especially among diabetic patients.

In recent years, major market players have started entering into distribution agreements with smaller firms to magnify their sales in regions beyond their direct sales channels' reach. For instance, Owen Mumford Ltd. signed an agreement with NIPRO Corporation, in July 2019. The former aims to increase the distribution channel of UniSafe springless devices in Japan through the latter, which is an Osaka-based firm. Other players following the same footprint include F. Hoffmann-La Roche Ltd., B. Braun Melsungen AG, and HTL-STREFA S.A.

According to P&S Intelligence, North America adopted the highest number of lancets in 2019, due to the rising prevalence of chronic diseases, surging population of elderly people, and increasing technological advancements, in the region. According to the Center for Disease Control and Prevention (CDC), in the U.S., more than 34 million individuals are living with diabetes. The CDC also states that nearly 600,000 deaths in the country occur due to cancer and approximately 1.7 million cases are registered every year.

Whereas, the Asia-Pacific lancet market will exhibit the fastest growth during the forecast period. This can be ascribed to the improving healthcare infrastructure, booming elderly population, magnifying purchasing power, rising prevalence of chronic ailments, and increasing number of initiatives by public and private organizations to spread awareness regarding diabetes. The United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP) propounds that by 2050, one in four people in the region will be over 60 years old. Further, the WHO states that around 6 million people in Southeast Asia have diabetes.

Thus, the increasing preference for minimally invasive procedures and the booming number of diabetic patients will propel the usage of lancets in the coming years.